Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous reslizumab in oral corticosteroid-dependent eosinophilic asthma
2015-001580-39Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma and eosinophilic asthma (EA) comparing Reslizumab subcutaneous with Placebo (2 arms). Primary endpoint: Categorized percent reduction in daily oral corticosteroid dose. Started Oct 2015; status: completed.
02
Drugs
reslizumab
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on 2015-001580-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001580-39.